Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Portal systemic encephalopathy.

S Schenker1, M K Bay

  • 1Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78282-7878, USA.

Clinics in Liver Disease
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioglitazone in the treatment of NASH: the role of adiponectin.

Alimentary pharmacology & therapeutics·2010
Same author

Failed jump landing trials: deficits in neuromuscular control.

Scandinavian journal of medicine & science in sports·2007
Same author

Does the NHS need celebrity chefs to spice up hospital food?

Nursing times·2002
Same author

In utero ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in fetal brain: a potential role for 4-hydroxynonenal.

Alcoholism, clinical and experimental research·2001
Same author

The effects of food restriction in man on hepatic metabolism of acetaminophen.

Clinical nutrition (Edinburgh, Scotland)·2001
Same author

Biphasic behavior of the high-spin-->low-spin relaxation of [Fe(btpa)](PF6)2 in solution (btpa = N,N,N',N'-tetrakis(2-pyridylmethyl)-6,6'-bis(aminomethyl)-2,2'- bipyridine).

Inorganic chemistry·2001
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

This review updates knowledge on Portal systemic encephalopathy (PSE), a type of hepatic encephalopathy. It covers pathogenesis and therapeutic strategies based on recent findings.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Neurology

Background:

  • Portal systemic encephalopathy (PSE) is a complex neurological complication of liver disease.
  • Understanding PSE is crucial for managing patients with advanced liver conditions.

Purpose of the Study:

  • To provide an updated overview of Portal systemic encephalopathy (PSE).
  • To discuss current understanding of PSE pathogenesis.
  • To analyze recent therapeutic advancements for PSE.

Main Methods:

  • Literature review of recent scientific data.
  • Synthesis of current knowledge on PSE.
  • Analysis of therapeutic strategies.

Main Results:

  • Recent data offer new insights into the pathogenesis of PSE.

Related Experiment Videos

  • Several therapeutic options for PSE have evolved.
  • Diagnosis is not covered due to lack of recent advancements.

    • Conclusions:

    • Continued research is vital for advancing PSE management.
    • Updated understanding of pathogenesis may lead to novel therapies.
    • Current therapeutic strategies focus on managing symptoms and underlying causes.